DLX1 acts as a novel prognostic biomarker involved in immune cell infiltration and tumor progression in lung adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Distal-less homeobox 1 (DLX1) is upregulated in lung adenocarcinoma (LUAD), acting as a poor prognostic factor. DLX1 knockdown inhibits LUAD cell growth, migration, and invasion, identifying it as a therapeutic target.
Area Of Science
- Oncology
- Molecular Biology
- Bioinformatics
Background
- The role of distal-less homeobox 1 (DLX1) in lung adenocarcinoma (LUAD) pathogenesis is not well understood.
- DLX1 is implicated in the initiation and progression of various cancers.
Purpose Of The Study
- To investigate the prognostic and immunologic significance of DLX1 in LUAD.
- To validate the functional role of DLX1 in LUAD cell behavior.
Main Methods
- Bioinformatic analysis using MethSurv and cBioPortal to assess DLX1 methylation, mutations, and prognostic value.
- Exploration of DLX1 expression and its correlation with immune cell infiltration.
- In vitro cellular functional assays to determine the impact of DLX1 knockdown on LUAD cells.
Main Results
- DLX1 mRNA expression is significantly upregulated in LUAD.
- High DLX1 expression and promoter methylation correlate with worse prognosis, establishing DLX1 as an independent prognostic factor.
- DLX1 expression is associated with immune cell infiltration and enrichment in cell cycle and DNA repair pathways.
- DLX1 knockdown suppresses LUAD cell proliferation, migration, and invasion.
Conclusions
- DLX1 serves as a potential diagnostic and prognostic biomarker in LUAD.
- DLX1 represents a promising therapeutic target for LUAD treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
